323 related articles for article (PubMed ID: 14682110)
1. Hematopoietic management in oncology practice. Part 1. Myeloid growth factors.
Glaspy JA
Oncology (Williston Park); 2003 Nov; 17(11):1593-603. PubMed ID: 14682110
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
3. The in vitro effects of granulocyte and granulocyte-macrophage colony-stimulating factor on interleukin-3-dependent proliferation of human neonatal circulating progenitor cells.
Bedford Russell AR; Davies EG; Gibson FM; Gordon-Smith EC
Pediatr Res; 1995 May; 37(5):630-3. PubMed ID: 7541523
[TBL] [Abstract][Full Text] [Related]
4. Clinical use of subcutaneous G-CSF or GM-CSF in malignancy.
Disis ML
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):5-9. PubMed ID: 15934493
[No Abstract] [Full Text] [Related]
5. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
6. [Hematopoietic growth factors in prophylaxis and therapy of infections complications in children with neutropenia].
Lehrnbecher T
Klin Padiatr; 2001; 213(4):212-38. PubMed ID: 11528556
[TBL] [Abstract][Full Text] [Related]
7. Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes.
Nagler A; Ginzton N; Negrin R; Bang D; Donlon T; Greenberg P
Leukemia; 1990 Mar; 4(3):193-202. PubMed ID: 1690318
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte and granulocyte macrophage colony-stimulating factors as therapy in human and veterinary medicine.
Fernández-Varón E; Villamayor L
Vet J; 2007 Jul; 174(1):33-41. PubMed ID: 17029990
[TBL] [Abstract][Full Text] [Related]
9. [GM-CSF and G-CSF: cytokines in clinical application].
Ruef C; Coleman DL
Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294
[TBL] [Abstract][Full Text] [Related]
10. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
Semin Oncol; 1994 Dec; 21(6 Suppl 16):33-8. PubMed ID: 7528449
[TBL] [Abstract][Full Text] [Related]
11. Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor.
Hellmich B; Schnabel A; Gross WL
Semin Arthritis Rheum; 1999 Oct; 29(2):82-99. PubMed ID: 10553980
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients.
Root RK; Dale DC
J Infect Dis; 1999 Mar; 179 Suppl 2():S342-52. PubMed ID: 10081506
[TBL] [Abstract][Full Text] [Related]
13. [Clinical use of granulocyte colony stimulating-factors (GM-CSF and G-CSF].
Borota R; Borota J; Belić A; Gebauer E; Stefanović N
Med Pregl; 1997; 50(3-4):87-93. PubMed ID: 9229690
[TBL] [Abstract][Full Text] [Related]
14. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
[TBL] [Abstract][Full Text] [Related]
15. [Application of CSF to cancer treatment].
Takaku F
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):739-46. PubMed ID: 2455478
[TBL] [Abstract][Full Text] [Related]
16. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
17. Effect of recombinant human granulocyte colony-stimulating factor administration in normal and experimentally infected newborn rats.
Iguchi K; Inoue S; Kumar A
Exp Hematol; 1991 Jun; 19(5):352-8. PubMed ID: 1709109
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation, part II: granulocyte colony-stimulating factors.
Bell SG
Neonatal Netw; 2006; 25(1):65-70. PubMed ID: 16514867
[TBL] [Abstract][Full Text] [Related]
20. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.
Gómez Raposo C; Pinto Marín A; González Barón M
Clin Transl Oncol; 2006 Oct; 8(10):729-34. PubMed ID: 17074671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
